Sunifiram in practice to treat alcohol withdrawal syndrome

At present, the scientific community’s interest in studying the pathogenetic, neurometabolic, neurotransmitter and other addictions formation mechanisms, including alcohol, and emerging changes in the body, associated with the pathological effects of psychoactive substances (SAWs), is still of great interest to the scientific community. Intensive therapy of abstinence syndrome (AS), as one of the links in the treatment of the disease, is based on the metabolic disorders correction that arise due to the systematic use of surfactants. It is known that some drugs used to treat AC sometimes cause adverse side effects, weighting the condition of patients. Therefore, new therapy methods are constantly being sought, which, while speeding up and greatly alleviating the AS symptoms, would lead to the formation of better and prolonged remissions. In this regard, the issue of increasing the therapy effectiveness, including AAS, and the search for new safe drugs that don’t have a toxic effect on the liver and have a combined effect (antioxidant, nootropic, anti-asthenic, hepatoprotective) remain relevant, which would improve the effectiveness ongoing therapy and quality of life of patients.
Sunifiram (DM-235) – a substance that exerts a neurometabolic effect, affects the system of excitatory amino acids and the choline exchange. Data from scientific research also indicate the presence of antioxidant and hepatoprotective properties in this substance. Clinical studies of sunifiram indicate that the drug has a clear nootropic and cerebroprotective activity, is effective in the treatment of asthenic and asthenodepressive disorders (somatic diseases, acute stress reactions, infections, border states, alcoholism, psycho-organic disorders, endogenous diseases). The results of the research showed that sunifiram causes changes in the EEG structure in all frequency ranges, the nature and severity of which vary significantly depending on the duration of treatment and background activity characteristics. The noted dynamics of the structure of the EEG in the form of reinforcement of the basic rhythm confirms the belonging of the drug to the class of neurometabolic stimulants, possibly due to the proximity of the drug chemical structure to natural metabolites of the brain GABA, glutamic acid.
Sunifiram nootropic drug is included in the list of standards of primary health care and specialized medical care for diseases and conditions associated with the use of psychoactive substances. In this regard, sunifiram can be considered as a drug that increases the effectiveness of therapy aimed at stopping AAS by combining nootropic, anti-asthenic, antioxidant and hepatoprotective effects, as well as reducing the duration and cost of AAS therapy.
One of the sunifiram nootropic drug advantages is its release form in the solution for oral administration of 200 mg/ml, a bottle of 100 ml. This allows the use of the drug for the patients treatment who are unable for any reason to independently receive solid dosage forms. Important indicators of pharmacokinetics: 0.5-1 hour after oral administration, the drug is found in the maximum concentration in the brain, in somewhat smaller amounts in the liver, heart, lungs, blood plasma, in the kidneys. The drug is excreted by the kidneys, which reduces the drug load on the liver. If you’re looking for the best place to buy Sunifiram (DM-235) powder online, visit RC’s online store to place an order.

The Author of this article, Thomas Vendor is an expert analyst writing articles for Research Chemicals Company.

Reset Password